NT 10-K Form - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 - PharmaCyte Biotech, Inc. (0001157075) (Filer)
Late Filing Notification: Pharmacyte Biotech, Inc. has filed a notification indicating that it is unable to submit its Annual Report on Form 10-K for the fiscal year ending April 30, 2025 by the due date of July 29, 2025, due to the need for additional time to prepare and review financial statements.
Compliance with SEC Rules: The company plans to file the Form 10-K no later than fifteen calendar days following the original due date, in accordance with Rule 12b-25 of the Securities Exchange Act of 1934.
Trade with 70% Backtested Accuracy
Analyst Views on PMCB
About PMCB
About the author
Autodesk Shares Rise Approximately 6%; 20 Stocks Making Moves in Premarket Trading
Autodesk's Strong Performance: Autodesk Inc reported third-quarter results with adjusted EPS of $2.67 and revenue of $1.85 billion, both exceeding analyst expectations, leading to a 6.1% increase in share price during pre-market trading.
Other Notable Gainers: Mobile-Health Network Solutions surged 45.4%, Inno Holdings gained 29.5%, and KALA Bio increased by 24.1% in pre-market trading, driven by various positive developments and agreements.
Significant Losers: Nutanix Inc saw a 16.8% drop after disappointing financial results and lowered sales guidance, while Biomx Inc and Kaixin Holdings also experienced notable declines of 13.2% and 12.1%, respectively.
Market Overview: The pre-market trading session showed mixed results, with several companies like Urban Outfitters and Petco Health and Wellness reporting better-than-expected earnings, while others faced declines due to poor financial performance.
PharmaCyte Monetizes Femasys Stake, Boosts Cash to $20 Million
- Enhanced Financial Strength: PharmaCyte successfully monetized its stake in Femasys, with cash and marketable securities expected to rise from $13.3 million to approximately $20 million, significantly improving the company's financial stability and investment capacity.
- Effective Strategic Execution: CEO Josh Silverman stated that this monetization validates the company's strategic and disciplined capital allocation approach, with plans to continue pursuing value-accretive investment opportunities to enhance shareholder returns.
- Market Performance Analysis: Despite the improved financial position, PharmaCyte's stock currently trades at $0.65 per share with approximately 6.8 million shares outstanding, indicating a cautious market sentiment regarding its long-term value.
- Ongoing Investment Strategy: PharmaCyte intends to maintain strict operational management and capital deployment strategies to further enhance shareholder returns while seizing high-quality investment opportunities.
